Lidocaine added to sedation during liver cancer ablation and its effect on inflammation
Tests adding lidocaine to propofol and fentanyl sedation in adults having liver cancer ablation.
Plain-language title generated from the registry record
Registry title: The Impact of Anaesthesia and Sedation on Inflammation and NETosis in Hepatocellular Carcinoma Ablation
Key facts
- Where
- Cluj-Napoca, RomaniaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07657897, who can take part
Where in Romania
- "Prof. Dr. Octavian Fodor" Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, RomaniaCluj-Napoca, RomaniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Iuliu Hatieganu University of Medicine and Pharmacy
- Trial code
- NCT07657897
- Record updated
- 21 July 2026
- Original description
According to recent literature, liver disease causes approximately 2 million deaths annually; 1 million are attributed to the complications of cirrhosis, while the remaining deaths are caused by hepatocellular carcinoma (HCC). The latter currently ranks 16th among the leading causes of death worldwide.Read full original descriptionShow less
The Impact of Anaesthesia on Inflammation and NETosis in Hepatocellular Carcinoma Resection
According to recent literature, liver disease causes approximately 2 million deaths annually; 1 million are attributed to the complications of cirrhosis, while the remaining deaths are caused by hepatocellular carcinoma (HCC). The latter currently ranks 16th among the leading causes of death worldwide.
Current research focuses on investigating novel therapeutic modalities, optimizing surgical and anesthetic practices, and identifying biological biomarkers to predict disease progression and severity. In this study, we address radiofrequency ablation (RFA) with the goal of improving periprocedural prognosis, recurrence rates, and overall survival. Specifically, we will quantify the expression of NETosis, a relatively novel biomarker with potential therapeutic and prognostic value in HCC progression. NETosis is a regulated form of cell death through which granulocytes release decondensed chromatin and various proteases into the extracellular space, forming a web-like meshwork known as neutrophil extracellular traps (NETs). These structures are actively involved in hepatic tumorigenesis by promoting tumor growth and metastasis.
Recent clinical data reveal that NETs play a key role in:
Local tumor progression
The incidence of hepatic metastasis
Direct modulation of the immune response
Hepatic ischemia-reperfusion injury
Several recent studies demonstrate that the in vivo blockade of NETosis reduces tumor recurrence, mitigates the pro-inflammatory state, and serves as a valuable prognostic indicator in advanced liver disease [2,3,4]. To suppress NETosis expression and ultimately lower recurrence rates, our protocol evaluates the intraprocedural administration of 1% lidocaine followed by a continuous postoperative intravenous lidocaine infusion.
Inclusion: patients with a hepatocellular carcinoma suitable for RFA; tumor measuring up to 3 cm in diameter; ASA I, II, or III.
Exclusion: candidates for surgery; chronic immunosuppressive medication; contraindications to any of the study medications; corticosteroid-dependent bronchial asthma; antiarrhythmic therapy; patients with psychiatric disorders; autoimmune disorders; congenital or acquired coagulation disorders; HIV-positive patients; pregnant women.